A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease: A Phase I Clinical Trial.
Qiaomei He, Xi Sun, Jiahua Niu...
https://pubmed.ncbi.nlm.nih.gov/38798038/Actively Recruiting
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-05-06
82
Participants Needed
1
Research Sites
52 weeks
Total Duration
Graft-versus-host disease GVHD is a serious complication after allogeneic hematopoietic stem cell transplantation, affecting survival and quality of life. Acute GVHD usually occurs within 100 days post-transplant, involving the skin, gastrointestinal tract, and liver, while chronic GVHD can develop months to years later. Despite current treatments like calcineurin inhibitors and post-transplant cyclophosphamide, recipients of haploidentical transplants from parous female donors remain at high risk for moderate-to-severe acute GVHD. This trial studies the effect of adding a selective JAK1 inhibitor, Ivarmacitinib, to standard low-dose ATG and cyclophosphamide to reduce GVHD in this high-risk group. Participants will receive rabbit anti-thymocyte globulin ATG at 2.5 mgkg on days -2 and -1 before transplant, cyclophosphamide 50 mgkg on day 3, and begin cyclosporine and mycophenolate mofetil on day 4. Ivarmacitinib, an oral JAK1 inhibitor, will be given at 4 mg daily from day -3 to 45, then reduced to 2 mg daily from day 46 to 60. This combination aims to prevent acute GVHD while preserving necessary immune functions. The study is a prospective, single-arm, multicenter trial focused on haploidentical peripheral blood stem cell transplantation from parous female donors. During the study, participants will be monitored for acute GVHD incidence up to 180 days post-transplant, graft failure by day 28, and non-relapse mortality by day 180. Assessments include regular clinical evaluations, laboratory tests, and safety monitoring. Participants are expected to comply with follow-up visits and related examinations throughout the study duration. The trial seeks to improve GVHD prevention and overall transplant outcomes in this high-risk population.
CONDITIONS
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
X
Xianmin Song, PhD
X
Xianmin Song, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 days
Participants receive low-dose rabbit ATG before transplantation.
2 visits (in-person) on Day -2 and Day -1
Duration - Approximately 63 days (Day -3 to Day +60)
Participants undergo haploidentical peripheral blood stem cell transplantation and receive post-transplant cyclophosphamide, cyclosporine/MMF, and Ivarmacitinib for acute GVHD prevention.
Daily oral medication from Day -3 to Day +60 with specific dosing changes; visits on Day +3 and Day +4 for additional treatments
Duration - Up to 180 days post-transplant
Participants are monitored for acute graft-versus-host disease and other outcomes up to 180 days post-transplant.
Regular visits for assessments up to Day +180
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Qiaomei He, Xi Sun, Jiahua Niu...
https://pubmed.ncbi.nlm.nih.gov/38798038/Jun Yang, Yannan Jia, Xiaoxia Hu...
https://pubmed.ncbi.nlm.nih.gov/41849227/Alison W Loren, Greta R Bunin, Christian Boudreau...
https://pubmed.ncbi.nlm.nih.gov/16785065/Sena Kim, Kidist Ashami, Sora Lim...
https://pubmed.ncbi.nlm.nih.gov/34304247/Kenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos...
https://pubmed.ncbi.nlm.nih.gov/27713092/James L M Ferrara, John E Levine, Pavan Reddy...
https://pubmed.ncbi.nlm.nih.gov/19282026/Bruce R Blazar, William J Murphy, Mehrdad Abedi
https://pubmed.ncbi.nlm.nih.gov/22576252/Xiaoqian Xu, Jun Yang, Yu Cai...
https://pubmed.ncbi.nlm.nih.gov/32873913/Xi Sun, Qiaomei He, Jun Yang...
https://pubmed.ncbi.nlm.nih.gov/34269100/Mark A Schroeder, H Jean Khoury, Madan Jagasia...
https://pubmed.ncbi.nlm.nih.gov/32324888/Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor